GSK3A and ovarian cancer: Furthermore, preliminary protein microarray analysis identified several potential GSK-3β phosphorylation sites which are targeted after ovarian cancer cells are treated with SLDM. Literature identifies that phosphorylation of S21 and Y279 inhibits GSK-3α activity [27,28].